French ophthalmology company Nicox (Euronext:COX) has announced it will replace its chief executive, Andreas Segerros, with current chief business officer Gavin Spencer.
While the firm provided few details on the decision, the change of leadership comes as part of a broader overhaul aimed at refocusing clinical priorities and extending cash reserves.
Nicox said it had reached an agreement in principle for an amendment to existing debt agreements, extending its cash runway to November 2024.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze